| __timestamp | Lantheus Holdings, Inc. | Neurocrine Biosciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 176081000 | 14400000 |
| Thursday, January 1, 2015 | 157939000 | 33800000 |
| Friday, January 1, 2016 | 164073000 | 35900000 |
| Sunday, January 1, 2017 | 169243000 | 1254000 |
| Monday, January 1, 2018 | 168489000 | 4889000 |
| Tuesday, January 1, 2019 | 172526000 | 7400000 |
| Wednesday, January 1, 2020 | 200649000 | 10100000 |
| Friday, January 1, 2021 | 237513000 | 14300000 |
| Saturday, January 1, 2022 | 353358000 | 23200000 |
| Sunday, January 1, 2023 | 586886000 | 39700000 |
| Monday, January 1, 2024 | 34000000 |
Unlocking the unknown
In the competitive landscape of biotechnology, cost efficiency is a critical factor for success. Over the past decade, Lantheus Holdings, Inc. and Neurocrine Biosciences, Inc. have demonstrated contrasting approaches to managing their cost of revenue. From 2014 to 2023, Lantheus Holdings saw a staggering 233% increase in their cost of revenue, peaking in 2023. This growth reflects their aggressive expansion and investment in new technologies. In contrast, Neurocrine Biosciences maintained a more conservative trajectory, with their cost of revenue increasing by approximately 176% over the same period. This strategic restraint may indicate a focus on optimizing existing operations rather than rapid expansion. As the biotech industry continues to evolve, these companies' differing strategies offer valuable insights into the balance between growth and efficiency.
Cost Insights: Breaking Down Biogen Inc. and Lantheus Holdings, Inc.'s Expenses
Cost of Revenue Comparison: BeiGene, Ltd. vs Lantheus Holdings, Inc.
Cost of Revenue: Key Insights for Neurocrine Biosciences, Inc. and Jazz Pharmaceuticals plc
Neurocrine Biosciences, Inc. vs Pharming Group N.V.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Neurocrine Biosciences, Inc. vs Alkermes plc
Cost of Revenue Comparison: Neurocrine Biosciences, Inc. vs CRISPR Therapeutics AG
Neurocrine Biosciences, Inc. vs Perrigo Company plc: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Neurocrine Biosciences, Inc. vs Amphastar Pharmaceuticals, Inc.
Cost of Revenue: Key Insights for Sarepta Therapeutics, Inc. and Lantheus Holdings, Inc.
Cost of Revenue Trends: Walgreens Boots Alliance, Inc. vs Lantheus Holdings, Inc.
Comparing Cost of Revenue Efficiency: Lantheus Holdings, Inc. vs CRISPR Therapeutics AG
Cost of Revenue Trends: Lantheus Holdings, Inc. vs PTC Therapeutics, Inc.